EA9161 A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)

Start Date: January 19, 2021

IRB Number: https://www.clinicaltrials.gov/ct2/show/NCT03701282

Condition/Disease: Cancer - Leukemia

Principal Investigator: Ding Wang, MD

Purpose of Research: cancer, blood cancer, leukemia, lymphocytic leukemia

Status: Accepting Participants

Phone: (313) 916-1784

Filter Results

Consent for Cookie Use